Korea University Anam Hospital
Seoul, 136-705, South Korea
NCT Number: NCT00966355
This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
Looking for future studies?
Notify Me16 year–75 year
All sexes
Interventional
Phase 4
Seoul, 136-705, South Korea
In patients who are suspected to have variceal bleedings, pharmacologic therapy with vasoactive drugs such as terlipressin, somatostatin, and octreotide is recommended as soon as possible, even before endoscopy. However, it is still unclear whether the efficacies of these drugs are same or not. This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
Other names: Glypressin
loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
Other names: Somatosan
loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
Other names: Sandostatin
Time frame: 5 days after enrollment
Time frame: 5 days after enrollment
at least one of the three criteria
Korea University
Other
RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07349654
Ascites Hepatic, Brain Diseases
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT04205396
Ascites, Brain Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT02756741
Blood-Borne Infections, Cardiovascular Diseases
View Trial DetailsNCT01188733
Cardiovascular Diseases, Cirrhosis
View Trial Details